We announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of marketing authorization in the European Union for mRNA-1345, an mRNA respiratory syncytial virus (RSV) vaccine. RSV is a highly contagious seasonal respiratory virus and a leading cause of lower respiratory tract infections and pneumonia. It causes a particularly high burden of disease in infants and older adults. In the European Union, RSV is estimated to cause approximately 160,000 hospital admissions in adults each year, with 92% of these admissions occurring in adults aged 65 and over. Learn more: https://lnkd.in/ey5GauYm
Thanks for sharing
Fantastic news on the positive opinion for mRNA-1345! This RSV vaccine could make a significant impact in protecting vulnerable populations.
You are a super star Eric.
Congrats Moderna Team!
Congrats Javier :) and Team
🤥🤥🤥
#cambridgepoison
Congrats!
The burden of RSV on vulnerable populations like infants and older adults is huge. This positive opinion from CHMP is a big step towards potentially reducing the impact of RSV in the European Union. BIOBOSTON CONSULTING